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Abstract Intracellular superoxide (O32 ) was manipulated in
M14 melanoma cells by overexpression or repression of Cu/Zn
SOD using a tetracycline-inducible expression system. Scaven-
ging intracellular O32 increased tumor cell sensitivity to
daunorubicin, etoposide, and pMC540, whereas expression of
the antisense SOD mRNA significantly decreased cell sensitivity
to drug treatment. Whereas Cu/Zn SOD overexpressing cells
exhibited higher activation of the executioner caspase 3 upon
drug exposure, caspase 3 activation was significantly lower when
Cu/Zn SOD was repressed by antisense expression. These data
show that intracellular O32 regulates tumor cell response to
drug-induced cell death via a direct or indirect effect on the
caspase activation pathway.
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1. Introduction
Intracellular reactive oxygen species (ROS) are produced
partly as byproducts of normal metabolism, and partly via
activation of ROS-producing enzymes in response to exoge-
nous stimuli [1^3]. Because intracellular accumulation of ROS
is toxic [1,4], levels of ROS are tightly regulated by multiple
defense mechanisms involving small anti-oxidant molecules
which contain sulfhydryl groups and ROS-scavenging en-
zymes, like superoxide dismutase (SOD), catalase, and gluta-
thione peroxidase [1,5]. Alterations of any of these compo-
nents of the oxidant defense system modulate the fate of
ROS in the cell by catalyzing reactions to remove O32 and
hydrogen peroxide (H2O2). The observation that tumor cells
often have lower SOD activity [6] has resulted in the notion
that an accumulation of intracellular ROS, or more generally
a pro-oxidant state, provides tumor cells with a survival ad-
vantage over their normal counterparts. One possible explan-
ation could be that O32 or H2O2 might function as mitogenic
stimuli [7]. However, our earlier ¢ndings suggest an important
role for O32 in tumor cell sensitivity to cell death induced by
cell surface receptor CD95 [8,9].
Most anticancer agents kill tumor cells by an active process
which involves key systems of the physiologic apoptosis pro-
gram [10^13], characterized by a series of events culminating
in speci¢c morphological and biochemical changes leading to
cell death [14^17]. The central executioners in the apoptotic
pathway are members of a family of intracellular cysteine
proteases, caspases [18]. Activation of one or other of the
caspase members can trigger a cascade of events leading to
cell death via proteolytic degradation of a number of cellular
proteins, e.g. lamin, actin, and poly(ADP-ribose) polymerase
[19^24].
Stimulated by these ¢ndings, we set out to investigate if the
inhibition of tumor cell death by increased intracellular O32 is
restricted to the CD95 system or could also be a mechanism
underlying tumor cell response to drug-induced cell death.
2. Materials and methods
2.1. Cells
Human melanoma cell line M14 was a generous gift from Dr.
Armando Bartolazzi (Oncologica Clinica e Sperimentale, Rome, Italy)
and was maintained in DMEM (Hyclone, Irvine, CA, USA) supple-
mented with 5% fetal bovine serum (FBS) (Hyclone), 1% glutamine
and 0.5% gentamicin (Gibco-BRL, Gaithersburg, MD, USA).
2.2. Cloning of Cu/Zn SOD cDNA in the sense or antisense orientation
Cu/Zn SOD cDNA was ampli¢ed using the Quick clone human
cDNA library from human leukocytes as template with the Advantage
cDNA PCR Kit (Clontech Laboratories, Inc., Palo Alto, CA, USA).
The following oligonucleotide primers were used to amplify the full
length Cu/Zn SOD cDNA: forward with a MluI restriction site 5P-
CAC GCG ACG CGT ATG GCG ACG AAG GCC GTG TGC
GTG CTG AAG-3P and reverse with a SalI restriction site 5P-CAC
GCG GTC GAC TTA TTG GGC GAT CCC AAT TAC ACC ACA
AGC-3P, whereas for antisense cDNA ampli¢cation we used: forward
with a SalI restriction site 5P-CAC GCG GTC GAC ATG GCG ACG
AAG GCC GTG TGC GTG CTG AAG-3P and reverse with a MluI
restriction enzyme site 5P-CAC GCG ACG CGT TTA TTG GGC
GAT CCC AAT TAC ACC ACA AGC-3P. The PCR ampli¢ed
SOD cDNA (464 bp) in the sense orientation was cloned into the
bidirectional vector pBiL, whereas the bidirectional vector pBiG was
used for antisense cloning. All vectors were purchased from Clontech.
2.3. Development of a tetracycline-responsive transactivator protein
expressing cell line
M14 cells were stably transfected with the pTet-o¡ plasmid. This
vector contains the gene for the tetracycline-responsive transactivator
protein (tTA protein) and a gene for resistance to geneticin (G418).
Stably transfected cells were selected using 1 mg/ml G418 (Gibco-
BRL). After 4^6 weeks, positive clones were screened for tTA expres-
sion by transient transfection with the pBiGL reporter. The pBiGL
reporter plasmid expresses both the LacZ and the luciferase genes,
which provides two functional assays for tTA regulatory protein ex-
pression. Two cell lines, M14 Tet-o¡ 1 and M14 Tet-o¡ E, gave high
L-galactosidase (‘L-Gal staining set’ from Boehringer Mannheim, In-
dianapolis, IN, USA) and luciferase (Luciferase Assay System from
Promega Corporation, Madison, WI, USA) activities in the absence
of tetracycline.
2.4. Development of Cu/Zn SOD and SOD antisense expressing M14
cell lines
M14 Tet-o¡ E was transfected for a second time with pBiL re-
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sponse plasmid containing the Cu/Zn SOD cDNA or the pBiG re-
sponse plasmid containing the antisense SOD cDNA, and the pTK-
Hyg plasmid containing the hygromycin resistance gene. Stably trans-
fected clones were screened for their ability to express L-galactosidase
or luciferase under the regulation of tetracycline. Two clones were
identi¢ed and ampli¢ed, the M14 SOD1 clone expressing Cu/Zn
SOD and M14 AS-SOD3 antisense clone. Transfections of all cell
lines were performed using the SuperFect Transfection Reagents
from Qiagen Gmbh (Germany) according to the vendor’s instructions.
2.5. Cell death triggers
Etoposide was obtained from Clontech, merocyanine 540 (MC540)
from Sigma Chemical Co. (St. Louis, MO, USA), and daunorubicin
(daunomycin hydrochloride) from ICN Biochemicals (Aurora, OH,
USA). MC540 was photoactivated (pMC540) as described elsewhere
[13].
2.6. Immuno£uorescence for intracellular Cu/Zn SOD
M14 cells (1U106) were ¢xed in 1 ml of 4% paraformaldehyde for
15 min on ice. After a wash with phosphate bu¡ered saline (PBS),
cells were permeabilized in ethanol for 1 h on ice, washed with PBS
and incubated with 1 Wg of monoclonal anti-Cu/Zn SOD IgG2a
(Pharmingen, San Diego, CA, USA) for 30 min on ice. Following
another wash with PBS+1% FBS samples were exposed to FITC-
conjugated goat anti-mouse IgG for 30 min, washed and resuspended
in 0.5 ml of 2% paraformaldehyde, and analyzed by £ow cytometry.
2.7. Chemiluminescence assay for detection of intracellular O32
The lucigenin-based chemiluminescence assay was performed as
previously described [8]. Chemiluminescence was monitored for 60 s
in a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA, USA).
Data are shown as relative light units per 60 s (RLU/60 s) þ S.D. from
three independent measurements.
2.8. Cytotoxicity assays
To trigger drug-induced cell death, 2U104 cells/well were plated in
96-well microtiter plates in DME+5% FBS 24 h prior to the test.
After 18 h of incubation with the anticancer drugs, the medium was
aspirated and crystal violet staining was used to assess cell viability as
described previously [8].
2.9. Annexin V staining for detection of apoptotic cells
Externalization of phosphatidylserine was assayed by the ApoAlert-
Annexin V Apoptosis kit (Clontech). Brie£y, M14 cells (1U106/ml)
were exposed to 20 WM etoposide or 150 Wg/ml of pMC540 or 0.4 Wg/
ml of daunorubicin for 12 h and cell surface staining and £ow cytom-
etry were performed as described elsewhere [13].
2.10. Determination of caspase 3 activity
Caspase 3 activity was assayed by the ApoAlert CPP32 Fluorescent
Assay kit (Clontech). M14 SOD1 and AS-SOD3 cells (1U106 cells/ml)
were exposed to etoposide (20 or 40 WM), pMC540 (150 Wg/ml) or
daunorubicin (0.4 Wg/ml) for 4^12 h. Cells were then resuspended in
50 Wl of chilled cell lysis bu¡er (provided by the supplier) and incu-
bated on ice for 10 min. 50 Wl of 2Ureaction bu¡er containing 10 mM
dithiothreitol and 5 Wl of the substrate DEVD-AFC were added to
each sample and incubated at 37‡C for 30 min. Detection of protease
activity was performed by measuring the relative £uorescence intensity
at 505 nm following excitation at 400 nm using a spectro£uorimeter
(Luminescence Spectrometer LS50B, Perkin Elmer, Buckinghamshire,
UK).
2.11. Western blot analysis
Lysates from the Cu/Zn SOD clone or the M14 AS-SOD3 clone
(5U106 cells) were prepared following incubation in the presence and
absence of 2 Wg/ml tetracycline using 0.5 ml of RIPA/NP-40 lysis
bu¡er (5 mM Tris pH 7.4, 30 mM NaCl, 1 mM EDTA, 1 mM
PMSF, 1 Wg/ml aprotinin, and 0.5% NP-40). 30 Wg of total protein
Fig. 1. Etoposide, pMC540, and daunorubicin induce apoptotic cell death in M14 cells. M14 cells (1U106 cells/ml) were exposed to 20 WM eto-
poside or 150 Wg/ml of pMC540 or 0.4 Wg/ml of daunorubicin for 18 h and cell death was determined by the crystal violet assay as described
in Section 2. To assess the e¡ect of caspase inhibitors on drug-induced cell death, M14 cells were treated with 100 WM DEVD-CHO or
YVAD-CHO prior to the addition of the three triggers. Data shown are mean þ S.D. of three independent experiments performed in triplicate.
B: M14 cells were treated as above for 12 h and externalization of PS was detected by annexin V-FITC (1 Wg/ml) staining and analyzed by
£ow cytometry. At least 10 000 events were analyzed by WINMDI software. Arrows indicate log increase in £uorescence over untreated control
cells. C: Caspase 3 activity was assayed in lysates of drug-exposed M14 cells (4^12 h) as described in Section 2. Data shown are representative
of at least three independent observations and expressed as fold increase in activity over the untreated M14 cells (1U).
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was subjected to 10% PAGE, transferred to nitrocellulose, blocked
overnight with 5% dried milk in Tris bu¡ered saline/0.1% Tween 20
(TBST), blotted with 2 Wg/ml of a polyclonal sheep anti-human Cu/Zn
SOD (UBI, Lake Placid, NY, USA) for 1 h at room temperature.
After three washes with TBST, the Cu/Zn SOD protein was detected
using 1:5000 dilution of an anti-sheep HRP-conjugated IgG (Pierce,
Rockford, IL, USA) and visualized by the SuperSignal Substrate
Western Blotting kit (Pierce). The autoradiogram was scanned using
the Scan Jet 4C/T scanner from Hewlett Packard and analyzed with
Desk Scan software. Results are shown in density level per square
inch (levelUsq.in).
3. Results
3.1. Etoposide, pMC540, and daunorubicin trigger cell death
via caspase 3 activation in M14 cells
Exposure of M14 cells to pMC540 (up to 150 Wg/ml) indu-
ces cell death by apoptosis [13]. Similar results were obtained
following exposure of M14 cells to 20 WM etoposide or 0.4 Wg/
ml of daunorubicin as shown in Fig. 1. We used annexin V
staining and caspase 3 activity as markers of apoptosis. All
three drugs induced cell death in M14 cells (Fig. 1A) with
characteristic apoptotic morphology (Fig. 1B), and induced
activation of caspase 3 (Fig. 1C). Caspase 3 activation was
detected as early as 4 h after treatment and peaked by 12 h
(Fig. 1C). The role of caspases in the death process induced
by etoposide, pMC540, and daunorubicin in M14 cells was
con¢rmed by the ability of YVAD-CHO (100 WM) and
DEVD-CHO (100 WM) to inhibit cell death (Fig. 1A). Hence,
through this set of experiments we demonstrate that all three
anticancer agents used in our study induced cell death in M14
melanoma cells via activation of the apoptotic machinery.
3.2. E¡ects of modulation of intracellular O32 on tumor cell
sensitivity to anticancer drugs via the caspase 3 activation
pathway
We used a tetracycline-inducible system whereby the expres-
sion of Cu/Zn SOD could be manipulated in vivo. Selective
gene expression is induced upon removal of tetracycline. Sta-
ble clones of M14 melanoma cell line were generated where
the level of Cu/Zn SOD protein could be increased by induc-
tion of transcription of Cu/Zn SOD cDNA (M14 SOD), or
decreased by transcription of an antisense SOD mRNA (M14
AS-SOD). In the absence of tetracycline for 48 h, the M14
SOD1 clone showed an increase of 1.78-fold (89%) in the
expression of Cu/Zn SOD protein compared to the same clone
where overexpression of Cu/Zn SOD was inhibited by the
presence of 2 Wg/ml tetracycline (Fig. 2). In contrast, the
M14 AS-SOD3 clone showed a 30% decrease in the Cu/Zn
SOD protein level when cultured in the absence of tetracycline
as shown in Fig. 2. It should be pointed out that in the
presence of tetracycline the level of SOD expression was not
signi¢cantly di¡erent in the two clones. Hence, the level of
SOD expression was 2.6-fold higher in the M14 SOD1 clone
than in M14 AS-SOD3 in the absence of tetracycline. In a
separate set of experiments, we con¢rmed our Western blot
data by immuno£uorescence staining for Cu/Zn SOD in the
clones (Table 1). In addition, to ascertain the e¡ect of over-
expression or repression of Cu/Zn SOD on the intracellular
O32 level, we directly measured intracellular O
3
2 using a lu-
cigenin-based chemiluminescence assay as described in Section
2. As shown in Table 1, M14 cells overexpressing Cu/Zn SOD
(M14 SOD ‘ON’) showed a drop in intracellular O32 concen-
tration, whereas antisense expression (M14 SOD antisense
‘ON’) resulted in an increase in O32 levels compared to the
clone cultured in the presence of tetracycline (M14 SOD anti-
sense ‘OFF’). An increase or decrease in Cu/Zn SOD level did
not a¡ect tumor cell survival in culture.
M14 SOD1 and M14 AS-SOD3 clones were subsequently
tested for their sensitivity to etoposide-, pMC540-, and dau-
norubicin-induced cell death in the presence or absence of
tetracycline. Overexpression of intracellular Cu/Zn SOD in
the M14 SOD1 clone, by removal of tetracycline for 48 h
(SOD ‘ON’), increased cell death in response to all anticancer
agents (Fig. 3A^C). In contrast, a decrease in Cu/Zn SOD
protein level in the M14 AS-SOD3 clone upon culturing with-
out tetracycline (SOD antisense ‘ON’) decreased sensitivity to
anticancer agents as compared to the sensitivity in the pres-
ence of tetracycline (SOD antisense ‘OFF’) (Fig. 3A^C). Fur-
thermore, whereas the percentage of cell death to all triggers
obtained with both M14 SOD1 and AS-SOD3 clones in the
‘OFF’ state was comparable, the percentage of cell death in
the SOD ‘ON’ state (higher sensitivity) was consistently 2^4-
fold higher as compared to that obtained with the cells in the
Fig. 2. Western blot analysis of Cu/Zn SOD expression in lysates of
M14 SOD1 and M14 AS-SOD3 clones. 5U106 of M14 SOD1 and
M14 AS-SOD3 clones were cultured in the presence of 2 Wg/ml of
tetracycline (+) or 48 h after the removal of tetracycline (3). West-
ern blot analysis of Cu/Zn SOD was performed as described in Sec-
tion 2.
Table 1
Analysis of intracellular Cu/Zn SOD and determination of intracel-
lular O32 concentration in SOD1 and AS-SOD3 clones
Clone Tet SOD-FITC (MFI) O32 (RLU/60 s) þ S.D.
SOD1 + 214 0.540 þ 0.059
3 386 0.262 þ 0.095
AS-SOD3 + 256 0.498 þ 0.06
3 180 0.588 þ 0.084
Intracellular Cu/Zn SOD was determined by £ow cytometry using
an anti-human Cu/Zn SOD IgG and secondary anti-mouse FITC-
conjugated IgG. 1U106 cells were stained and 10 000 events were
analyzed. Data are shown as mean £uorescence intensity (MFI).
For detection of intracellular O32 , 2U10
6 cells were lysed as de-
scribed in Section 2, and O32 was immediately measured by a lucige-
nin-based chemiluminescence assay. Data are shown as relative light
units/60 s (RLU/60 s), and indicate mean þ S.D. of three indepen-
dent measurements.
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SOD antisense ‘ON’ state (lower sensitivity). These data in-
dicate that intracellular level of Cu/Zn SOD can regulate sen-
sitivity of tumor cells to a variety of anticancer drugs. To
con¢rm that this e¡ect was mediated via O32 , we tested the
e¡ect of tiron, an O32 scavenger [25]. Our results (Fig. 4A,B)
demonstrate that preincubation of M14 cells in the SOD anti-
sense ‘ON’ state with 1 mM tiron (SOD antisense ‘ON’/tiron)
enhanced tumor cell death sensitivity to daunorubicin and
etoposide compared to that obtained when the SOD antisense
was not expressed (SOD antisense ‘OFF’). Moreover, the
presence of tiron in the SOD antisense ‘OFF’ (SOD antisense
‘OFF’/tiron) state further increased tumor cell sensitivity to
both cell death triggers to a level similar to that observed
when M14 cells were overexpressing SOD (SOD ‘ON’)
(Figs. 3A,C and 4A,B). We addressed the possibility that
the increase in tumor cell sensitivity to anticancer agents in
response to overexpression of SOD may be due to increased
production of H2O2. However, co-culturing cells with catalase
did not inhibit the increase in tumor cell death in response to
anticancer agents in cells tailored to overexpress Cu/Zn SOD
(data not shown).
The caspase 3 activities correlated with the cytotoxicity
data. Exposure to 20 WM etoposide resulted in a 2.4-fold in-
crease in caspase 3 activity in the presence of tetracycline
(SOD ‘OFF’ and AS-SOD ‘OFF’), but caspase 3 activity
was higher in the SOD ‘ON’ (3.4-fold increase in activity
over the control cells) than in the SOD antisense ‘ON’ state
(1.8-fold increase in activity over the control cells) as shown in
Fig. 5A. Similar results were obtained with 0.4 Wg/ml of dau-
norubicin and 150 Wg/ml of pMC540 (Fig. 5B and data not
shown).
4. Discussion
Evidence for the involvement of ROS in tumor promotion
derives from the earlier observations that free radical scav-
engers could inhibit numerous actions of tumor promoters
[26]. Thus a pro-oxidant state might provide tumor cells
with a survival advantage over their normal counterparts
[9,26]. Here we provide evidence that the intracellular O32
level is a central regulator of tumor cell response to apoptosis
induced by a variety of anticancer drugs. Since our previous
report showed inhibition of CD95-induced apoptosis by intra-
cellular O32 [8], one possible explanation for our results could
have been an indirect activation of the CD95 pathway in M14
cells following incubation with the di¡erent drugs [27^30].
However, M14 melanoma cells are de¢cient in both the death
receptors CD95 and CD120a [8], and none of the apoptotic
triggers used in our study induced expression of either of the
receptors (S. Pervaiz and M.-V. Cle¤ment, unpublished data).
In order to investigate the inhibitory e¡ect of increased
intracellular O32 concentration on apoptotic cell death, we
manipulated the intracellular O32 level by overexpressing or
decreasing the cytoplasmic Cu/Zn SOD protein level in vivo
using a tetracycline-inducible expression system. This allows
the same clone to be analyzed in the presence or absence of
tetracycline. M14 cells tailored to overexpress or suppress cy-
toplasmic Cu/Zn SOD showed a direct relationship between
intracellular Cu/Zn SOD, O32 concentrations, and tumor cell
sensitivity to apoptotic triggers. Overexpression of Cu/Zn
SOD enhanced tumor cell sensitivity to drug treatment, in
agreement with a recent ¢nding that overexpression of Cu/
Zn SOD increased sensitivity of mouse neurons transgenic
for Cu/Zn SOD to apoptosis induced by kainic acid [31].
Conversely, our results with the M14 antisense SOD clone
demonstrated that a decrease in intracellular Cu/Zn SOD in
tumor cells protected them from apoptosis induced by anti-
cancer drugs. The role of intracellular O32 in regulating tu-
Fig. 3. Sensitivity of the M14 SOD1 clone and the M14 AS-SOD3
clone to cell death triggered by increasing concentrations of etopo-
side or pMC540 or daunorubicin. Cell death of the M14 SOD1
clone and the M14 AS-SOD3 clone in the presence of tetracycline
(SOD ‘OFF’ or SOD antisense ‘OFF’) or following removal of tet-
racycline for 48 h (SOD ‘ON’ or SOD antisense ‘ON’) was deter-
mined following 18 h treatment with increasing concentrations of
(A) etoposide, (B) pMC540 or (C) daunorubicin.
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mor cell sensitivity thus appears not to be exclusive for CD95
signaling-dependent apoptosis, but may be common to a va-
riety of anticancer drugs known to induce cell death by acti-
vation of the apoptotic machinery. We addressed the possibil-
ity that the increase in tumor cell sensitivity to anticancer
agents, in response to overexpression of SOD, may be due
to increased production of H2O2. However, co-culturing cells
with catalase did not inhibit the increase in tumor cell death in
response to anticancer agents in cells tailored to overexpress
Cu/Zn SOD (data not shown). These data are further sup-
ported by a recent report which demonstrates that Cu/Zn
SOD overexpressing cells have reduced steady-state level of
O32 as well as H2O2 and an increased reducing environment
[32]. In light of our ¢ndings, the survival advantage that a
pro-oxidant environment provides the tumor cells may well
be a function of not only increased proliferation of cells
[7,33], but also resistance to apoptotic signal.
Through these series of experiments we have established
that intracellular O32 regulates tumor cell sensitivity to
drug-induced apoptosis. However, the intracellular target of
O32 remains unde¢ned. One logical candidate could be the
caspases, the central executioner of the apoptotic pathway
[34]. Indeed, an increase in Cu/Zn SOD level facilitated cas-
pase 3 activation, whereas a decrease of Cu/Zn SOD protein
Fig. 4. E¡ect of tiron on the sensitivity of the M14 AS-SOD3 clone to cell death induced by daunorubicin or etoposide. M14 AS-SOD3 cul-
tured with (SOD antisense ‘OFF’) or without (SOD antisense ‘ON’) 2 Wg/ml tetracycline was tested for sensitivity to (A) daunorubicin or (B)
etoposide in the presence of 1 mM tiron (SOD antisense ‘OFF’/tiron and SOD antisense ‘ON’/tiron). Cell death was determined by the crystal
violet assay.
Fig. 5. Caspase 3 activation following induction of cell death with daunorubicin and etoposide. The M14 SOD1 and M14 AS-SOD3 clones
were incubated with 20 WM (A) etoposide for 4^12 h, or (B) daunorubicin (0.4 Wg/ml) for 12 h in the presence of 2 Wg/ml tetracycline (SOD
‘OFF’ and SOD antisense ‘OFF’) or 48 h after the removal of tetracycline (SOD ‘ON’ and SOD antisense ‘ON’). Caspase activity is repre-
sented as fold increase over the activity obtained for cells without the apoptotic trigger (1U).
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level lowered caspase 3 activation, thus suggesting that regu-
lation of tumor cell sensitivity to apoptotic triggers by intra-
cellular O32 may be via its e¡ect on intracellular caspase
activation. Is the e¡ect of scavenging intracellular O32 directly
on caspase activation or on events upstream of the caspase
cascade? The targets of O32 in the regulation of tumor cell
response to apoptosis are the subjects of our ongoing inves-
tigations.
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